GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Price-to-Tangible-Book

Regen BioPharma (Regen BioPharma) Price-to-Tangible-Book : (As of Jun. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Price-to-Tangible-Book?

As of today (2024-06-14), Regen BioPharma's share price is $1.10. Regen BioPharma's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $-1.26. Hence, Regen BioPharma's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Regen BioPharma's Price-to-Tangible-Book or its related term are showing as below:

During the past 11 years, Regen BioPharma's highest Price to Tangible Book Ratio was 234.51. The lowest was 63.33. And the median was 148.92.

RGBP's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.775
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Regen BioPharma's share price is $1.10. Regen BioPharma's Book Value per Sharefor the quarter that ended in Mar. 2024 was $-1.26. Hence, Regen BioPharma's P/B Ratio of today is .


Regen BioPharma Price-to-Tangible-Book Historical Data

The historical data trend for Regen BioPharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Price-to-Tangible-Book Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regen BioPharma's Price-to-Tangible-Book

For the Biotechnology subindustry, Regen BioPharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Price-to-Tangible-Book falls into.



Regen BioPharma Price-to-Tangible-Book Calculation

Regen BioPharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=1.10/-1.258
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Regen BioPharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.